The Positive Side of the Alzheimer’s Disease Amyloid Cross-Interactions: The Case of the Aβ 1-42 Peptide with Tau, TTR, CysC, and ApoA1
Open accessThe DOI matches its Crossref record; 254 of the 256 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) represents a progressive amyloidogenic disorder whose advancement is widely recognized to be connected to amyloid-β peptides and Tau aggregation. However, several other processes likely contribute to the development of AD and some of them might be related to protein-protein interactions. Amyloid aggregates usually contain not only single type of amyloid protein, but also other type of proteins and this phenomenon can be rationally explained by the process of protein cross-seeding and co-assembly. Amyloid cross-interaction is ubiquitous in amyloid fibril formation and so a better knowledge of the amyloid interactome could help to further understand the mechanisms of amyloid related diseases. In this review, we discuss about the cross-interactions of amyloid-β peptides, and in particular Aβ1-42, with other amyloids, which have been presented either as integrated part of Aβ neurotoxicity process (such as Tau) or conversely with a preventive role in AD pathogenesis by directly binding to Aβ (such as transthyretin, cystatin C and apolipoprotein A1). Particularly, we will focus on all the possible therapeutic strategies aiming to rescue the Aβ toxicity by taking inspiration from these protein-protein interactions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





![Figure 6 (A) Interaction structure of the CysC-Aβ complex revealed by molecular dynamics simulation in the study of Przybylski et al. [186] (B) The binding complex from the docking output between Aβ and CysC fragment in the study of Sharma et al. [188].](https://figures.cochat.ai/paper-figures/bbab80daba5a471099eedf3fad19f17e/the-positive-side-of-the-alzheimers-disease-amyloid-cross-interactions-the-case-figure-6.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In contrast, the interaction between Aβ and transthyretin (TTR) is a favored PPI, because it reduces Aβ aggregation and toxicity.588”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [588]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Shin, W. S., Di, J., Murray, K. A., Sun, C., Li, B., Bitan, G., & Jiang, L. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00268 · Cited by 18 · cited 1×
“Transduction of Aβ oligomers into the cells enhances more the Tau-aggregation than Aβ-fibrils [82].”
BackgroundRetractedNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“Others, instead, support the idea that it is mainly Tau that plays the major role in the etiopathology, essentially for two reasons: firstly because Tau tangles can be found in patients’ brain even when extracellular Aβ deposits are not present [57], and secondly because evidences proved that intracellular Tau tangles…”
BackgroundThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 2×
“the accumulation of Aβ exacerbates Tau’s pathology [6,55,56].”
BackgroundOverdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,732
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 1×
“[19] Several other factors seem to contribute to the development of AD, thus questioning the amyloid cascade hypothesis and revealing its complex process linked by multiple interconnected events that cannot be easily explained by a single hypothesis.”
BackgroundScheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade
Chiti, F., & Dobson, C. M. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045115 · Cited by 2,629 · cited 1×
“All of them are characterized by the aggregation of misfolded proteins which have been found to adopt the same amyloid β-sheet-rich architecture, as part of their nature [1,2].”
BackgroundCopper, iron and zinc in Alzheimer's disease senile plaques
Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L., & Markesbery, W. R. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00092-6 · Cited by 2,120 · cited 2×
“In AD patients, the metals ions levels detected in cerebral amyloid plaques drastically grow up and, for example, the total copper concentration could increase up to 400 μM [131].”
BackgroundCryo-EM structures of tau filaments from Alzheimer’s disease
Fitzpatrick, A. W. P., Falcon, B., He, S., Murzin, A. G., Murshudov, G., Garringer, H. J., Crowther, R. A., Ghetti, B., Goedert, M., & Scheres, S. H. W. (2017) · Nature · doi:10.1038/nature23002 · Cited by 2,061
Alzheimer's Disease and the Amyloid-β Peptide
Murphy, M. P., & LeVine, H. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1221 · Cited by 1,750 · cited 1×
“In amyloid plaques, in the gray matter of the brain, the two classical lesions are the depositions of intracellular neurofibrillary tau tangles and the extracellular deposits of aggregated amyloid-β (Aβ) peptides [5].”
Nissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707
The role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661 · cited 1×
“Alternatively, Apo-E may sequester Aβ and promote cellular uptake and degradation of Apo-E-Aβ complexes [16].”
BackgroundKivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618 · cited 1×
“Besides, men with high levels of LDL cholesterol, meaning low levels of HDL and ApoA1, are more at risk to develop AD [234].”
BackgroundEnhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611
Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526
Molecular physiology of reverse cholesterol transport.
Fielding, C. J., & Fielding, P. E. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39898-9 · Cited by 1,448
Amyloid β-protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathways
Bitan, G., Kirkitadze, M. D., Lomakin, A., Vollers, S. S., Benedek, G. B., & Teplow, D. B. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222681699 · Cited by 1,287
Amyloid-β and tau--a toxic pas de deux in Alzheimer’s disease
Ittner, L. M., & Götz, J. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2967 · Cited by 1,269
Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242 · cited 1×
“For example, apolipoprotein E (Apo-E), the major cholesterol carrier, has an important role in modulating Aβ metabolism, aggregation and deposition [15].”
BackgroundA three-dimensional human neural cell culture model of Alzheimer’s disease
Choi, S. H., Kim, Y. H., Hebisch, M., Sliwinski, C., Lee, S., D’Avanzo, C., Chen, H., Hooli, B., Asselin, C., Muffat, J., et al. (2014) · Nature · doi:10.1038/nature13800 · Cited by 1,195 · cited 1×
“Thanks to the development of a 3D AD human neuronal cell culture model displaying both extracellular Aβ-deposits (plaques) and the concomitant presence of p-Tau in neurons and fibrillar Tau aggregates like NFT in neurites and cell bodies [86,87], Kwak et al.”
BackgroundProtein misfolding, aggregation, and conformational strains in neurodegenerative diseases
Soto, C., & Pritzkow, S. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0235-9 · Cited by 1,180 · cited 1×
“A great number of works concerning Aβ and Tau together, both in vitro and in vivo, supports the cross-seeding theory [61,62] or, better, the interaction and the synergistic effects [63] of these misfolded proteins.”
BackgroundRole of tau protein in both physiological and pathological conditions
AVILA, J., LUCAS, J. J., PÉREZ, M., & HERNÁNDEZ, F. (2004) · Physiological Reviews · doi:10.1152/physrev.00024.2003 · Cited by 1,005 · cited 2×
“spliced and the transcription leads to the formation of six Tau isoforms [42,43], displaying three or”
BackgroundInitiation and Synergistic Fibrillization of Tau and Alpha-Synuclein
Giasson, B. I., Forman, M. S., Higuchi, M., Golbe, L. I., Graves, C. L., Kotzbauer, P. T., Trojanowski, J. Q., & Lee, V. M.-Y. (2003) · Science · doi:10.1126/science.1082324 · Cited by 879 · cited 1×
“Some experiments suggested that tau and α-synuclein can influence each other, accelerating their respective fibrillization process and resulting in the formation of pathological inclusions in neurodegenerative diseases [29].”
BackgroundSegrest, J., Jones, M., De Loof, H., Brouillette, C., Venkatachalapathi, Y., & Anantharamaiah, G. (1992) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41536-6 · Cited by 866
The cystatins: Protein inhibitors of cysteine proteinases
Turk, V., & Bode, W. (1991) · FEBS Letters · doi:10.1016/0014-5793(91)80804-c · Cited by 820
apoE isoform–specific disruption of amyloid β peptide clearance from mouse brain
Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., & Zlokovic, B. V. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36663 · Cited by 771 · cited 1×
“In addition, Apo-E might modulate Aβ removal from the brain to the systemic circulation by transporting Aβ across the blood-brain barrier [17].”
BackgroundThe case for rejecting the amyloid cascade hypothesis
Herrup, K. (2015) · Nature Neuroscience · doi:10.1038/nn.4017 · Cited by 768 · cited 1×
“Among these factors, we could count lysosomal disfunction, loss of Ca2+ homeostasis, neuroinflammation, progressive oxidative damage and problems related to glucose metabolism [20,21].”
BackgroundTau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease
Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2362 · Cited by 734
Fibril in senile systemic amyloidosis is derived from normal transthyretin.
Westermark, P., Sletten, K., Johansson, B., & Cornwell, G. G. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.7.2843 · Cited by 696 · cited 1×
“Familial amyloid cardiomyopathy (FAC) is a rare autosomal-dominant disease associated to the deposition of TTR amyloid plaques in the myocardium [107] and related to the most common TTR mutation Val122Ile [108].”
BackgroundZempel, H., Thies, E., Mandelkow, E., & Mandelkow, E.-M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2357-10.2010 · Cited by 686 · cited 2×
“the accumulation of Aβ exacerbates Tau’s pathology [6,55,56].”
BackgroundThree dimensions of the amyloid hypothesis: time, space and 'wingmen'
Musiek, E. S., & Holtzman, D. M. (2015) · Nature Neuroscience · doi:10.1038/nn.4018 · Cited by 662 · cited 1×
“Among these factors, we could count lysosomal disfunction, loss of Ca2+ homeostasis, neuroinflammation, progressive oxidative damage and problems related to glucose metabolism [20,21].”
BackgroundHe, Z., Guo, J. L., McBride, J. D., Narasimhan, S., Kim, H., Changolkar, L., Zhang, B., Gathagan, R. J., Yue, C., Dengler, C., et al. (2018) · Nature Medicine · doi:10.1038/nm.4443 · Cited by 645 · cited 1×
“All these results were successively confirmed by in vivo experiments and revealed the propagating potential of heterotopic seeding of filamentous Tau-aggregates induced by Aβ along functionally connected brain regions [77,79,81].”
ResultAβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice
McGowan, E., Pickford, F., Kim, J., Onstead, L., Eriksen, J., Yu, C., Skipper, L., Murphy, M. P., Beard, J., Das, P., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.06.030 · Cited by 637 · cited 1×
“It has been proved for example that transgenic mice expressing high level of Aβ1-40 do not develop Aβ plaque [92] and that Aβ1-40 stabilizes Aβ1-42 monomers by competing for binding site on pre-existing Aβ1-42 aggregates, thus inhibiting further aggregation [93].”
BackgroundPropagation of Tau aggregates and neurodegeneration
Goedert, M., Eisenberg, D. S., & Crowther, R. A. (2017) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-072116-031153 · Cited by 632
Role of Tau as a Microtubule-Associated Protein: Structural and Functional Aspects
Barbier, P., Zejneli, O., Martinho, M., Lasorsa, A., Belle, V., Smet-Nocca, C., Tsvetkov, P. O., Devred, F., & Landrieu, I. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00204 · Cited by 617
Masliah, E., Rockenstein, E., Veinbergs, I., Sagara, Y., Mallory, M., Hashimoto, M., & Mucke, L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211412398 · Cited by 607
Arboleda-Velasquez, J. F., Lopera, F., O’Hare, M., Delgado-Tirado, S., Marino, C., Chmielewska, N., Saez-Torres, K. L., Amarnani, D., Schultz, A. P., Sperling, R. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0611-3 · Cited by 598 · cited 1×
“More recently, it has been shown that a homozygous APOE3ch mutation can impart resistant to the clinical onset of AD pathogenesis, probably having beneficial effects on downstream tau pathology and neurodegeneration, even in the face of high Aβ plaque burden [18].”
BackgroundAmyloid-β-independent regulators of tau pathology in Alzheimer disease
van der Kant, R., Goldstein, L. S. B., & Ossenkoppele, R. (2020) · Nature reviews. Neuroscience · doi:10.1038/s41583-019-0240-3 · Cited by 580 · cited 2×
“in patients with AD, indicate that Aβ plaque deposition precedes cortical Tau pathology [54] and that”
BackgroundClinton, L. K., Blurton-Jones, M., Myczek, K., Trojanowski, J. Q., & LaFerla, F. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0490-10.2010 · Cited by 576
Schweers, O., Schönbrunn-Hanebeck, E., Marx, A., & Mandelkow, E. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)51080-8 · Cited by 567
Neve, R. L., Harris, P., Kosik, K. S., Kurnit, D. M., & Donlon, T. A. (1986) · Molecular Brain Research · doi:10.1016/0169-328x(86)90033-1 · Cited by 565 · cited 1×
“It is encoded by a single gene, MAPT, on chromosome 17 containing 16 exons [41].”
BackgroundThe preclinical phase of the pathological process underlying sporadic Alzheimer’s disease
Braak, H., & Del Tredici, K. (2015) · Brain · doi:10.1093/brain/awv236 · Cited by 540 · cited 1×
“Others, instead, support the idea that it is mainly Tau that plays the major role in the etiopathology, essentially for two reasons: firstly because Tau tangles can be found in patients’ brain even when extracellular Aβ deposits are not present [57], and secondly because evidences proved that intracellular Tau tangles…”
BackgroundDomain swapping: entangling alliances between proteins.
Bennett, M. J., Choe, S., & Eisenberg, D. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3127 · Cited by 532 · cited 1×
“Until then, all the crystallization experiments had led to obtain the dimeric form of CysC as a result of a 3D domain swapping, the same structural arrangement firstly observed in diphtheria toxin [169,170] (Figure 5B).”
Wakabayashi, K., Tanji, K., Mori, F., & Takahashi, H. (2007) · Neuropathology · doi:10.1111/j.1440-1789.2007.00803.x · Cited by 516
Abrahamson, M., Barrett, A. J., Salvesen, G., & Grubb, A. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67380-6 · Cited by 504 · cited 1×
“In healthy people, the CysC concentration in the CSF is six times higher than that of blood plasma [158], as a result of a large expression of this protein by the brain tissue (neurons, astrocytes, endothelial, and microglial cells) [159].”
BackgroundResolving controversies on the path to Alzheimer's therapeutics
Selkoe, D. J. (2011) · Nature Medicine · doi:10.1038/nm.2460 · Cited by 494 · cited 2×
“studies in this field, more and more evidences revealed that Tau and Aβ are strictly and mutually interconnected in AD pathogenesis [53].”
BackgroundAntiamyloidogenic and Neuroprotective Functions of Cathepsin B: Implications for Alzheimer's Disease
Mueller-Steiner, S., Zhou, Y., Arai, H., Roberson, E. D., Sun, B., Chen, J., Wang, X., Yu, G., Esposito, L., Mucke, L., et al. (2006) · Neuron · doi:10.1016/j.neuron.2006.07.027 · Cited by 465 · cited 2×
“Cathepsin B (CatB), one of the enzymes implicated in Aβ degradation, cle ves the C-terminal of Aβ1-42 peptides decreasing the Aβ levels [181].”
BackgroundCrystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation
Borhani, D. W., Rogers, D. P., Engler, J. A., & Brouillette, C. G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12291 · Cited by 434 · cited 4×
“The N-terminal fragment, es ential for the stabilization of the secondary structure of ApoA1 [200], is g nerally highly conserved in apolipoprotein-derived amyloidosis and seems to have an importan role in the forma ion of amyloid fibrils [190,201–204], in particular in those amyloidosis affecting pat ents with chroni…”
BackgroundInfluentialAlzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers
De Felice, F. G., Wu, D., Lambert, M. P., Fernandez, S. J., Velasco, P. T., Lacor, P. N., Bigio, E. H., Jerecic, J., Acton, P. J., Shughrue, P. J., et al. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.029 · Cited by 432
Schwarz, A. J., Yu, P., Miller, B. B., Shcherbinin, S., Dickson, J., Navitsky, M., Joshi, A. D., Devous, M. D., & Mintun, M. S. (2016) · Brain · doi:10.1093/brain/aww023 · Cited by 425
Transthyretin sequesters amyloid beta protein and prevents amyloid formation.
Schwarzman, A. L., Gregori, L., Vitek, M. P., Lyubski, S., Strittmatter, W. J., Enghilde, J. J., Bhasin, R., Silverman, J., Weisgraber, K. H., & Coyle, P. K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8368 · Cited by 413 · cited 1×
“the major Aβ binding protein in CSF and its interaction with Aβ inhibits the amyloid formation [116].”
BackgroundTau impairs neural circuits, dominating amyloid-β effects, in Alzheimer models in vivo
Busche, M. A., Wegmann, S., Dujardin, S., Commins, C., Schiantarelli, J., Klickstein, N., Kamath, T. V., Carlson, G. A., Nelken, I., & Hyman, B. T. (2019) · Nature Neuroscience · doi:10.1038/s41593-018-0289-8 · Cited by 413 · cited 1×
“A great number of works concerning Aβ and Tau together, both in vitro and in vivo, supports the cross-seeding theory [61,62] or, better, the interaction and the synergistic effects [63] of these misfolded proteins.”
BackgroundHuman cystatin C, an amyloidogenic protein, dimerizes through three-dimensional domain swapping.
Janowski, R., Kozak, M., Jankowska, E., Grzonka, Z., GRUBB, A. O., Abrahamson, M., & Jaskólski, M. (2001) · Nature Structural Biology · doi:10.1038/86188 · Cited by 403 · cited 1×
“Until then, all the crystallization experiments had led to obtain the dimeric form of CysC as a result of a 3D domain swapping, the same structural arrangement firstly observed in diphtheria toxin [169,170] (Figure 5B).”
Garwood, C. J., Pooler, A. M., Atherton, J., Hanger, D. P., & Noble, W. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.50 · Cited by 379 · cited 1×
“To date, three main suggested mechanism have been hypothesized: (1) Aβ species seem to interacts with kinases, thus enhancing the phosphorylation of Tau and its detaching from microtubule with consequently aggregation [64–68], (2) the Aβ-induced Tau phosphorylation is mediated by soluble inflammatory factors from astr…”
BackgroundProtein–protein interactions in human disease
RYAN, D., & MATTHEWS, J. (2005) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2005.06.001 · Cited by 375 · cited 1×
“Amyloid formation can be considered an abnormal protein-protein interaction process [22].”
BackgroundAn, S., & Fu, L. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.09.005 · Cited by 363 · cited 1×
“Thus, by taking inspiration from the heterobifunctional PROTAC approach [248,249] and with the purpose of boosting the positive interaction between two amyloid proteins, two covalently linked protein-binding molecules or peptidomimetics can be designed in this type of protein-protein interaction and exploit as a new t…”
BackgroundHDL-targeted therapies: progress, failures and future
Kingwell, B. A., Chapman, M. J., Kontush, A., & Miller, N. E. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4279 · Cited by 354 · cited 19×
“Besides, men with high levels of LDL cholesterol, meaning low levels of HDL and ApoA1, are more at risk to develop AD [234].”
BackgroundInfluentialWestermark, P., Benson, M. D., Buxbaum, J. N., Cohen, A. S., Frangione, B., Ikeda, S.-I., Masters, C. L., Merlini, G., Saraiva, M. J., & Sipe, J. D. (2005) · Amyloid · doi:10.1080/13506120500032196 · Cited by 341 · cited 1×
“In vivo, ApoA1 has been identified as an myloidogenic pro ein among other apolipoproteins [199].”
BackgroundGSK3: a possible link between beta amyloid peptide and tau protein
Hernández, F., Gómez de Barreda, E., Fuster-Matanzo, A., Lucas, J. J., & Avila, J. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.011 · Cited by 327
Proteomic Characterization of Postmortem Amyloid Plaques Isolated by Laser Capture Microdissection
Liao, L., Cheng, D., Wang, J., Duong, D. M., Losik, T. G., Gearing, M., Rees, H. D., Lah, J. J., Levey, A. I., & Peng, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403672200 · Cited by 323 · cited 1×
“Some studies revealed that Aβ is just the major amyloid protein of the 488 proteins in AD related amyloid plaque [24].”
BackgroundFormation and Metabolism of Prebeta-Migrating, Lipid-Poor Apolipoprotein A-I
Rye, K.-A., & Barter, P. J. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000104029.74961.f5 · Cited by 309 · cited 1×
“About 95% of the protein is bound to mature HDL but a few ApoA1 circulate in a lipid-free form [198].”
BackgroundApolipoprotein A-I: structure–function relationships
Frank, P. G., & Marcel, Y. L. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32028-9 · Cited by 308
Amyloid Activates GSK-3β to Aggravate Neuronal Tauopathy in Bigenic Mice
Terwel, D., Muyllaert, D., Dewachter, I., Borghgraef, P., Croes, S., Devijver, H., & Van Leuven, F. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070904 · Cited by 300
Bloedon, L. T., Dunbar, R., Duffy, D., Pinell-Salles, P., Norris, R., DeGroot, B. J., Movva, R., Navab, M., Fogelman, A. M., & Rader, D. J. (2008) · Journal of Lipid Research · doi:10.1194/jlr.p800003-jlr200 · Cited by 292
Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Aβ toxicity
Buxbaum, J. N., Ye, Z., Reixach, N., Friske, L., Levy, C., Das, P., Golde, T., Masliah, E., Roberts, A. R., & Bartfai, T. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712197105 · Cited by 284 · cited 1×
“Sometimes one amyloid protein which inhibits the amyloid fibril formation of another amyloid protein, simultaneously reduces the toxicity of the aggregate, like the effects that transthyretin (TTR) has on Aβ1-42 [30].”
BackgroundBolmont, T., Clavaguera, F., Meyer-Luehmann, M., Herzig, M. C., Radde, R., Staufenbiel, M., Lewis, J., Hutton, M., Tolnay, M., & Jucker, M. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070403 · Cited by 281
Merched, A., Xia, Y., Visvikis, S., Serot, J. M., & Siest, G. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00103-7 · Cited by 272
A 3D human neural cell culture system for modeling Alzheimer's disease
Kim, Y. H., Choi, S. H., D'Avanzo, C., Hebisch, M., Sliwinski, C., Bylykbashi, E., Washicosky, K. J., Klee, J. B., Brüstle, O., Tanzi, R. E., et al. (2015) · Nature Protocols · doi:10.1038/nprot.2015.065 · Cited by 269 · cited 1×
“Thanks to the development of a 3D AD human neuronal cell culture model displaying both extracellular Aβ-deposits (plaques) and the concomitant presence of p-Tau in neurons and fibrillar Tau aggregates like NFT in neurites and cell bodies [86,87], Kwak et al.”
BackgroundSynphilin-1 is present in Lewy bodies in Parkinson's disease
Wakabayashi, K., Engelender, S., Yoshimoto, M., Tsuji, S., Ross, C. A., & Takahashi, H. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200004)47:4<521::aid-ana18>3.0.co;2-b · Cited by 266
Transthyretin: a review from a structural perspective
Hamilton, J. A., & Benson, M. D. (2001) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000791 · Cited by 264
Ran, X., & Gestwicki, J. E. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.06.004 · Cited by 263 · cited 1×
“This is normally the reason why small molecules often lack selectivity [149].”
BackgroundGuo, J.-P., Arai, T., Miklossy, J., & McGeer, P. L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509386103 · Cited by 261
Cerebrospinal fluid transthyretin: aging and late onset Alzheimer's disease
Serot, J.-M., Christmann, D., Dubost, T., & Couturier, M. (1997) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.63.4.506 · Cited by 257
Models of β-amyloid induced Tau-pathology: The long and “folded” road to understand the mechanism
Stancu, I.-C., Vasconcelos, B., Terwel, D., & Dewachter, I. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-51 · Cited by 256 · cited 1×
“To date, three main suggested mechanism have been hypothesized: (1) Aβ species seem to interacts with kinases, thus enhancing the phosphorylation of Tau and its detaching from microtubule with consequently aggregation [64–68], (2) the Aβ-induced Tau phosphorylation is mediated by soluble inflammatory factors from astr…”
BackgroundJouanne, M., Rault, S., & Voisin-Chiret, A.-S. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.070 · Cited by 252
Saito, T., Mihira, N., Matsuba, Y., Sasaguri, H., Hashimoto, S., Narasimhan, S., Zhang, B., Murayama, S., Higuchi, M., Lee, V. M. Y., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.009487 · Cited by 248 · cited 1×
“All these results were successively confirmed by in vivo experiments and revealed the propagating potential of heterotopic seeding of filamentous Tau-aggregates induced by Aβ along functionally connected brain regions [77,79,81].”
ResultEnhanced tau aggregation in the presence of Amyloid β
Bennett, R. E., DeVos, S. L., Dujardin, S., Corjuc, B., Gor, R., Gonzalez, J., Roe, A. D., Frosch, M. P., Pitstick, R., Carlson, G. A., et al. (2017) · The American Journal of Pathology · doi:10.1016/j.ajpath.2017.03.011 · Cited by 245
The amyloid deposits in Alzheimer's disease: their nature and pathogenesis.
Glenner, G. G., Wong, C. W., Quaranta, V., & Eanes, E. D. (1984) · PubMed · Cited by 244
Isolation and characterization of the human apolipoprotein A-I gene.
Karathanasis, S. K., Zannis, V. I., & Breslow, J. L. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.20.6147 · Cited by 242 · cited 1×
“Its mature form is essentially expressed in he small i testi e and in th liv r [190,197].”
BackgroundBailey, D., Jahagirdar, R., Gordon, A., Hafiane, A., Campbell, S., Chatur, S., Wagner, G. S., Hansen, H. C., Chiacchia, F. S., Johansson, J., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.035 · Cited by 234
Variant apolipoprotein AI as a major constituent of a human hereditary amyloid
Nichols, W. C., Dwulet, F. E., Liepnieks, J., & Benson, M. D. (1988) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(88)80909-4 · Cited by 233 · cited 2×
“The G26R mutation has been associated to hereditary amyloidosis leading to renal failure [213,218].”
BackgroundSun, B., Zhou, Y., Halabisky, B., Lo, I., Cho, S.-H., Mueller-Steiner, S., Devidze, N., Wang, X., Grubb, A., & Gan, L. (2008) · Neuron · doi:10.1016/j.neuron.2008.10.001 · Cited by 231 · cited 3×
“In another study the CatB-deficient mice were analyzed and the CysC overexpression decreased the total amyloid plaque deposit [182].”
BackgroundInfluentialPathology, diagnosis and pathogenesis of AA amyloidosis
Röcken, C., & Shakespeare, A. (2002) · Virchows Archiv · doi:10.1007/s00428-001-0582-9 · Cited by 222 · cited 3×
“protofilaments of ApoA1 present a β-strand-loop-β-strand structure [205,217].”
BackgroundDomain Conformation of Tau Protein Studied by Solution Small-Angle X-ray Scattering
Mylonas, E., Hascher, A., Bernadó, P., Blackledge, M., Mandelkow, E., & Svergun, D. I. (2008) · Biochemistry · doi:10.1021/bi800900d · Cited by 218
Weisgraber, K. H., Bersot, T. P., Mahley, R. W., Franceschini, G., & Sirtori, C. R. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109957 · Cited by 216
High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits.
Jj, B., Badimón, L., Galvez, A., Dische, R., & Fuster, V. (1989) · PubMed · Cited by 214
Cross‐seeding effects of amyloid β‐protein and α‐synuclein
Ono, K., Takahashi, R., Ikeda, T., & Yamada, M. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07847.x · Cited by 210
Lewis, T. L., Cao, D., Lu, H., Mans, R. A., Su, Y. R., Jungbauer, L., Linton, M. F., Fazio, S., LaDu, M. J., & Li, L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.127829 · Cited by 208 · cited 1×
“These results seem to suggest an indirect role of ApoA1, which would rather reduce neuroinflammation and cerebral amyloid angiopathy than directly bind to Aβ [237].”
BackgroundMechanisms of Amyloid-β Peptide Clearance: Potential Therapeutic Targets for Alzheimer's Disease
Yoon, S.-S., & AhnJo, S.-M. (2012) · Biomolecules and Therapeutics · doi:10.4062/biomolther.2012.20.3.245 · Cited by 205 · cited 2×
“Overall impairment in Aβ clearance is also a major contributor to disease development [13].”
BackgroundChen, W.-T., Liao, Y.-H., Yu, H.-M., Cheng, I. H., & Chen, Y.-R. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.177246 · Cited by 199
Mei, X., & Atkinson, D. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.260422 · Cited by 199 · cited 2×
“To date, two different human ApoA1 truncate structures are present in the PDB data bank (PDB code: 1AV1 [200] and 3R2P [210]).”
BackgroundVasconcelos, B., Stancu, I.-C., Buist, A., Bird, M., Wang, P., Vanoosthuyse, A., Van Kolen, K., Verheyen, A., Kienlen-Campard, P., Octave, J.-N., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1525-x · Cited by 192 · cited 1×
“All these results were successively confirmed by in vivo experiments and revealed the propagating potential of heterotopic seeding of filamentous Tau-aggregates induced by Aβ along functionally connected brain regions [77,79,81].”
ResultThe Effects of Altered Apolipoprotein A-I Structure on Plasma HDL Concentration
Sorci-Thomas, M. G., & Thomas, M. J. (2002) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(01)00163-3 · Cited by 189 · cited 2×
“These ApoA1 variants have undeniable interest because they may affect lecithin-cholesterol acyltransferase (LCAT) activity and promote the formation of amyloidosis [190].”
BackgroundDi Scala, C., Yahi, N., Boutemeur, S., Flores, A., Rodriguez, L., Chahinian, H., & Fantini, J. (2016) · Scientific Reports · doi:10.1038/srep28781 · Cited by 186 · cited 1×
“The mechanism behind this interaction is currently unknown but the hypothesis of a channels/pores formation induced by Aβ oligomers does not seem plausible because these latter should appear in a shorter amount of time (1 to 2 h) [83] respect to the incubation time needed to prime cells and enhance Tau-aggregation.”
BackgroundMetal ions as modulators of protein conformation and misfolding in neurodegeneration
Leal, S. S., Botelho, H. M., & Gomes, C. M. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.04.004 · Cited by 183
A mutation in apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy
Nichols, W. C., Gregg, R. E., Brewer, H. B., & Benson, M. D. (1990) · Genomics · doi:10.1016/0888-7543(90)90288-6 · Cited by 176 · cited 1×
“The G26R mutation has been associated to hereditary amyloidosis leading to renal failure [213,218].”
BackgroundProteomic identification of novel proteins associated with Lewy bodies
Xia, Q. (2008) · Frontiers in Bioscience · doi:10.2741/2973 · Cited by 176
Codeposition of Cystatin C with Amyloid-β Protein in the Brain of Alzheimer Disease Patients
Levy, E., Sastre, M., Kumar, A., Gallo, G., Piccardo, P., Ghetti, B., & Tagliavini, F. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.1.94 · Cited by 170 · cited 1×
“The co-localization of CysC and Aβ has been observed in the cerebral arteries of patients affected by cerebral amyloid angiopathy (CAA) [174], in parenchymal and vascular amyloid deposits in brains of patients with Alzheimer disease [175] and in sporadic inclusion-body myositis (sIBM) muscle fibers [176].”
BackgroundInterfering peptides targeting protein–protein interactions: the next generation of drugs?
Bruzzoni‐Giovanelli, H., Alezra, V., Wolff, N., Dong, C., Tufféry, P., & Rebollo, A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.10.016 · Cited by 169 · cited 1×
“Monoclonal antibodies and other protein therapeutics have the advantage to be selective, but they suffer from poor oral bioavailability, high cost and susceptibility to proteolysis [150].”
BackgroundCornwell, G. G., Sletten, K., Johansson, B., & Westermark, P. (1988) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(88)90188-x · Cited by 168 · cited 1×
“In aged patients, the fibrils accumulation in organs and tissue induces the onset of senile systemic amyloidosis diseases (SSA) [105,106].”
BackgroundGordon, J. I., Sims, H. F., Lentz, S. R., Edelstein, C., Scanu, A. M., & Strauss, A. W. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)32773-x · Cited by 167 · cited 1×
“Human ApoA-1 is synthesized as preproapoA-1, a 267 amino acid precursor ap lipopr tein, which undergoes intracellular co-translational proteolytic cleavage into proapoA-1 and suc essively proapoA-1 is cleaved to mature pla ma ApoA1 in human plasma [195,196].”
BackgroundWeisgraber, K. H., Rall, S. C., Bersot, T. P., Mahley, R. W., Franceschini, G., & Sirtori, C. R. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)32955-7 · Cited by 164
Cross-talk between amyloidogenic proteins in type-2 diabetes and Parkinson’s disease
Horvath, I., & Wittung-Stafshede, P. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610371113 · Cited by 159 · cited 1×
“For example, islet amyloid polypeptide (IAPP) was reported to promote the α-synuclein amyloid formation, which can explain why type-2 diabetes patients are susceptible to developing PD [28].”
BackgroundNeurobiological pathways to Alzheimer's disease: Amyloid-beta, TAU protein or both?
Paula, V. D. J. R. D., Guimarães, F. M., Diniz, B. S., & Forlenza, O. V. (2009) · Dementia & Neuropsychologia · doi:10.1590/s1980-57642009dn30300003 · Cited by 155 · cited 1×
“Others, instead, support the idea that it is mainly Tau that plays the major role in the etiopathology, essentially for two reasons: firstly because Tau tangles can be found in patients’ brain even when extracellular Aβ deposits are not present [57], and secondly because evidences proved that intracellular Tau tangles…”
BackgroundBinding of cystatin C to Alzheimer’s amyloid β inhibits in vitro amyloid fibril formation
Sastre, M., Calero, M., Pawlik, M., Mathews, P. M., Kumar, A. R., Danilov, V., Schmidt, S. D., Nixon, R. A., Frangione, B., & Levy, E. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.11.006 · Cited by 151 · cited 3×
“During their ELISA affinity assay, they found that the monoclonal antibody 6E10, which binds to residues 1–17 of Aβ, abolished the CysC binding to Aβ-coated plates, thus suggesting that the binding site within Aβ is within the amino-terminal domain of the peptide [164].”
BackgroundKwak, S. S., Washicosky, K. J., Brand, E., von Maydell, D., Aronson, J., Kim, S., Capen, D. E., Cetinbas, M., Sadreyev, R., Ning, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15120-3 · Cited by 151 · cited 1×
“provided a direct evidence that it exists a direct correlation between Aβ species and Tau pathology in AD [88].”
BackgroundCystatin C modulates cerebral β-amyloidosis
Kaeser, S. A., Herzig, M. C., Coomaraswamy, J., Kilger, E., Selenica, M.-L., Winkler, D. T., Staufenbiel, M., Levy, E., Grubb, A., & Jucker, M. (2007) · Nature Genetics · doi:10.1038/ng.2007.23 · Cited by 150
Hereditary Apolipoprotein AI-Associated Amyloidosis in Surgical Pathology Specimens
Eriksson, M., Schönland, S. O., Yumlu, S., Hegenbart, U., von Hutten, H., Владиславовна, Г. З., Lohse, P., Büttner, J., Schmidt, H., & Röcken, C. (2009) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2009.080161 · Cited by 147
Luo, J., Wärmländer, S. K. T. S., Gräslund, A., & Abrahams, J. P. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.r116.714576 · Cited by 146 · cited 2×
“ApoA1 is assumed to be an amyloid protein able to decrease the Aβ fibrilization by affecting in vitro the morphology of the fibrils [23,231].”
BackgroundApolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis.
Soutar, A. K., Hawkins, P. N., Vigushin, D. M., Tennent, G. A., Booth, S. E., Hutton, T., Nguyen, O., Totty, N. F., Feest, T. G., & Hsuan, J. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7389 · Cited by 145 · cited 1×
“The hereditary one, the most frequent form, involves mutants of ApoA1 responsible of a systemic amyloidosis [212,213].”
BackgroundStructure, function and amyloidogenic propensity of apolipoprotein A-I
Obici, L. P., Franceschini, G., Calabresi, L., Giorgetti, S., Stoppini, M., Merlini, G., & Bellotti, V. (2006) · Amyloid · doi:10.1080/13506120600960288 · Cited by 144 · cited 2×
“So far, among the 50 ApoA1 variants described [193], about half of them are known to be”
BackgroundFundamentals of cross-seeding of amyloid proteins: an introduction
Ren, B., Zhang, Y., Zhang, M., Liu, Y., Zhang, D., Gong, X., Feng, Z., Tang, J., Chang, Y., & Zheng, J. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb01871a · Cited by 144 · cited 1×
“A great number of works concerning Aβ and Tau together, both in vitro and in vivo, supports the cross-seeding theory [61,62] or, better, the interaction and the synergistic effects [63] of these misfolded proteins.”
BackgroundMechanisms of Transthyretin Inhibition of β-Amyloid Aggregation In Vitro
Li, X., Zhang, X., Ladiwala, A. R. A., Du, D., Yadav, J. K., Tessier, P. M., Wright, P. E., Kelly, J. W., & Buxbaum, J. N. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2561-13.2013 · Cited by 143 · cited 4×
“It has been reported that TTR binds to soluble, oligomeric and Aβ fibrils [121,123] performing its relevant role in Aβ clearance, however it is not clear which form of TTR binds to Aβ.”
BackgroundInfluentialKoudinov, A., Matsubara, E., Frangione, B., & Ghiso, J. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2788 · Cited by 141 · cited 1×
“demonstrated that ApoA1-containing HDL particles can bind to circulating Aβ peptide, as revealed by SDS PAGE and immunoblot analysis [223,224].”
Backgroundα-Helix targeting reduces amyloid-β peptide toxicity
Nerelius, C., Sandegren, A., Sargsyan, H., Raunak, R., Leijonmarck, H., Chatterjee, U., Fisahn, A., Imarisio, S., Lomas, D. A., Crowther, D. C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810364106 · Cited by 140 · cited 1×
“One of the strategies adopted to stop or reverse the progression of the disease is to modulate or inhibit the aggregation process of Aβ, by various mechanisms: stabilization of its native state, destabilization of its incorrectly folded state [8], bypass of the on-pathway oligomer formation, inhibition of the fibril e…”
BackgroundAvila, J., Jiménez, J. S., Sayas, C. L., Bolós, M., Zabala, J. C., Rivas, G., & Hernández, F. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00262 · Cited by 140
Cystatin C in aging and in Alzheimer’s disease
Mathews, P. M., & Levy, E. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.06.003 · Cited by 133 · cited 1×
“or function related to several CNS aging-dependent diseases [173].”
BackgroundAmyloid-β pathology enhances pathological fibrillary tau seeding induced by Alzheimer PHF in vivo
Vergara, C., Houben, S., Suain, V., Yilmaz, Z., Decker, R. D., Dries, V. V., Boom, A., Mansour, S., Leroy, K., Ando, K., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1953-5 · Cited by 133
Folding-related Dimerization of Human Cystatin C
Ekiel, I., & Abrahamson, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.3.1314 · Cited by 132 · cited 1×
“In vitro experiments showed that a slight change in pH or temperature and the addition of small amount of denaturing agents induce the dimerization and oligomerization of wild-type CysC [162,163].”
BackgroundKoldamova, R. P., Lefterov, I. M., Lefterova, M. I., & Lazo, J. S. (2001) · Biochemistry · doi:10.1021/bi002186k · Cited by 131 · cited 3×
“ApoA1 has a positive effect on Aβ, preventing fibril formation and attenuating Aβ toxicity [231].”
BackgroundLefterov, I., Fitz, N. F., Cronican, A. A., Fogg, A., Lefterov, P., Kodali, R., Wetzel, R., & Koldamova, R. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.127738 · Cited by 129 · cited 1×
“The inhibition of Aβ1-42 aggregation is ApoA1 concentration-dependent [238].”
BackgroundFibrillogenic Oligomers of Human Cystatin C Are Formed by Propagated Domain Swapping
Wahlbom, M., Wang, X., Lindström, V., Carlemalm, E., Jaskolski, M., & Grubb, A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611368200 · Cited by 128 · cited 2×
“Some studies suggested that the swapping dimerization could be the mechanism by which CysC forms oligomers and fibrils [163,171,172], moreover the relationship between the CysC swapping dimerization and its fibrillization has not been clarified yet.”
BackgroundAmyloid β Protein: Aβ40 Inhibits Aβ42 Oligomerization
Murray, M. M., Bernstein, S. L., Nyugen, V., Condron, M. M., Teplow, D. B., & Bowers, M. T. (2009) · Journal of the American Chemical Society · doi:10.1021/ja8092604 · Cited by 128 · cited 1×
“It has been proved for example that transgenic mice expressing high level of Aβ1-40 do not develop Aβ plaque [92] and that Aβ1-40 stabilizes Aβ1-42 monomers by competing for binding site on pre-existing Aβ1-42 aggregates, thus inhibiting further aggregation [93].”
BackgroundLerch, P. G., Förtsch, V., Hodler, G., & Bolli, R. (1996) · Vox Sanguinis · doi:10.1046/j.1423-0410.1996.7130155.x · Cited by 128 · cited 1×
“Furthermore, reconstituted HDL (ApoA1 + soy phosphatidylcholine) [245] were tested on mice to study if they could lower plasma levels of Aβ.”
MethodGomes, L. A., Hipp, S. A., Rijal Upadhaya, A., Balakrishnan, K., Ospitalieri, S., Koper, M. J., Largo-Barrientos, P., Uytterhoeven, V., Reichwald, J., Rabe, S., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02053-5 · Cited by 125 · cited 1×
“PrPC behaves as an interaction partner of soluble Aβ oligomers and intervenes in p-Tau propagation by activating, once complexed with Aβ, a signaling pathway that increase the levels of p-Tau [100].”
BackgroundRobertson, N., & Spring, D. R. (2018) · Molecules · doi:10.3390/molecules23040959 · Cited by 123 · cited 2×
“All these disadvantages pushed researchers to study peptides and peptidomimetics as promising therapeutics in the field of protein-protein interactions, because they can afford selectivity and affinity, thanks to their size in midway between small-molecules and protein therapeutics [148].”
BackgroundAbelein, A., Abrahams, J. P., Danielsson, J., Gräslund, A., Jarvet, J., Luo, J., Tiiman, A., & Wärmländer, S. K. T. S. (2014) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-014-1131-8 · Cited by 122 · cited 1×
“The formation of their ordered molecular structure can be also revealed by fluorescence spectroscopy with thioflavine T and Congo red dyes [3].”
BackgroundHuman apolipoprotein A–I binds amyloid-β and prevents Aβ-induced neurotoxicity
Paula-Lima, A. C., Tricerri, M. A., Brito-Moreira, J., Bomfim, T. R., Oliveira, F. F., Magdesian, M. H., Grinberg, L. T., Panizzutti, R., & Ferreira, S. T. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.12.003 · Cited by 121 · cited 2×
“ApoA1 interferes with Aβ-induced lipid peroxidation and, in the presence of ApoA1, Aβ aggregates are less neurotoxic than pure Aβ fibrils [201].”
BackgroundStructure-based inhibitors of amyloid beta core suggest a common interface with tau
Griner, S. L., Seidler, P., Bowler, J., Murray, K. A., Yang, T. P., Sahay, S., Sawaya, M. R., Cascio, D., Rodriguez, J. A., Philipp, S., et al. (2019) · eLife · doi:10.7554/elife.46924 · Cited by 121 · cited 1×
“In a recent study [97] the crystal structure of an Aβ core segment (Aβ16-26) has been determined by Micro Electron Diffraction (ED) and, starting from these results, peptide-based inhibitors of Aβ aggregation have been designed.”
BackgroundBenson, M. (2003) · Baillière's Best Practice & Research : Clinical Rheumatology · doi:10.1016/j.berh.2003.09.001 · Cited by 120 · cited 3×
“protofilaments of ApoA1 present a β-strand-loop-β-strand structure [205,217].”
BackgroundLi, X., & Buxbaum, J. N. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-79 · Cited by 119
Conformational mimicry in Alzheimer's disease. Role of apolipoproteins in amyloidogenesis.
Wısnıewskı, T., Golabek, A. A., Kida, E., Wisniewski, K. E., & Frangione, B. (1995) · Europe PMC (PubMed Central) · Cited by 117
Nalivaeva, N. N., Belyaev, N. D., Kerridge, C., & Turner, A. J. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00235 · Cited by 116
Plasma Transthyretin as a Candidate Marker for Alzheimer's Disease
Velayudhan, L., Killick, R., Hye, A., Kinsey, A. M., Güntert, A., Lynham, S., Ward, M. A., Leung, R., Lourdusamy, A., To, A. W. M., et al. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110611 · Cited by 113 · cited 1×
“The strategy of using TTR stabilization as a therapeutic target in AD needs to be accurately evaluated taking into account that TTR is decreased in CSF and in sera of AD patients [147] and also considering that TTR monomers seem to bind more Aβ than do tetramers [125].”
MethodApolipoprotein A1-derived amyloid in human aortic atherosclerotic plaques.
Westermark, P., Mucchiano, G. I., Marthin, T., Johnson, K. H., & Sletten, K. (1995) · Europe PMC (PubMed Central) · Cited by 113
Molecular regulation of macrophage reverse cholesterol transport
Wang, X., & Rader, D. J. (2007) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3281ec5113 · Cited by 113
Hereditary Cystatin C Amyloid Angiopathy: Genetic, Clinical, and Pathological Aspects
A, P., AO, S., & L, T. (2006) · Brain Pathology · doi:10.1111/j.1750-3639.2006.tb00561.x · Cited by 112 · cited 1×
“A single point mutation of CysC (Leu68Gln) leads to hereditary cystatin C amyloid angiopathy (HCCAA) [165].”
BackgroundIbáñez, B., Giannarelli, C., Cimmino, G., Santos‐Gallego, C. G., Alique, M., Pinero, A., Vilahur, G., Fuster, V., Badimón, L., & Badimón, J. J. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.10.006 · Cited by 111
Prevention of Domain Swapping Inhibits Dimerization and Amyloid Fibril Formation of Cystatin C
Nilsson, M., Wang, X., Rodziewicz‐Motowidło, S., Janowski, R., Lindström, V., Önnerfjord, P., Westermark, G. T., Grzonka, Z., Jaskólski, M., & GRUBB, A. O. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402621200 · Cited by 110 · cited 1×
“Some studies suggested that the swapping dimerization could be the mechanism by which CysC forms oligomers and fibrils [163,171,172], moreover the relationship between the CysC swapping dimerization and its fibrillization has not been clarified yet.”
BackgroundThe Role of Cystatin C in Cerebral Amyloid Angiopathy and Stroke: Cell Biology and Animal Models
Levy, E., Jaskólski, M., & GRUBB, A. O. (2006) · Brain Pathology · doi:10.1111/j.1750-3639.2006.tb00562.x · Cited by 110 · cited 2×
“Several studies reported that CysC plays a protective role against several pathological manifestations such as tumor metastasis, inflammation, viral and bacterial infections and neurodegenerative disorders [166].”
BackgroundCathepsin B Degrades Amyloid-β in Mice Expressing Wild-type Human Amyloid Precursor Protein
Wang, C., Sun, B., Zhou, Y., Grubb, A., & Gan, L. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.371641 · Cited by 107 · cited 1×
“The majority of AD patients do not possess the FAD mutation, so the same experiment was carried out on hAPP wild type (hAPPWT) showing that CysC-CatB affects Aβ levels in hAPPWT mice in a similar manner as in hAPPFAD mice [183].”
ResultMiller, Y., Ma, B., & Nussinov, R. (2011) · Biochemistry · doi:10.1021/bi200400u · Cited by 106 · cited 1×
“The Aβ core sequence is implied not only in self aggregation but it seems to be also involved in the cross-seeding interaction with Tau VQIINK and VQIVYK sequences as demonstrated by previous in vitro and in vivo studies [34] and by computational seeding models [98].”
Characterization of the Interaction of β-Amyloid with Transthyretin Monomers and Tetramers
Du, J., & Murphy, R. M. (2010) · Biochemistry · doi:10.1021/bi101280t · Cited by 104 · cited 3×
“A second binding region was identified in the EF helix which is highly solvent exposed and thus less restricted in the TTR tetramer [125].”
BackgroundMethodAlemi, M., Gaiteiro, C., Ribeiro, C. A., Santos, L. M., Gomes, J. R., Oliveira, S. M., Couraud, P.-O., Weksler, B., Romero, I., Saraiva, M. J., et al. (2016) · Scientific Reports · doi:10.1038/srep20164 · Cited by 104 · cited 1×
“It has been hypothesized that TTR binds to Aβ and this established complex, through the LRP1 receptor, is transported outside of the brain towards the liver [127].”
BackgroundCrystal structure of human cystatin C stabilized against amyloid formation
Kolodziejczyk, R., Michalska, K., Hernández‐Santoyo, A., Wahlbom, M., GRUBB, A. O., & Jaskólski, M. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2010.07596.x · Cited by 103
Koudinov, A. R., Berezov, T. T., Kumar, A. R., & Koudinova, N. V. (1998) · Clinica Chimica Acta · doi:10.1016/s0009-8981(97)00207-6 · Cited by 102 · cited 1×
“ApoA1 levels are also found to be significantly lower in AD patients compared to controls [223] whereas high levels of ApoA1 are associated in lowering risks of dementia [232].”
ResultMańczak, M., & Reddy, P. H. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130275 · Cited by 99 · cited 2×
“The observation of co-localization of oligomeric Aβ and phosphorylated Tau in AD brain patients led some research groups to think that a mutual cross-interaction between the two amyloid proteins might be responsible of the pathological behavior of both proteins [60].”
BackgroundKanellis, P., Romans, A. Y., Johnson, B. J., Kercret, H., Chiovetti, R., Allen, T. M., & Segrest, J. P. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)70314-7 · Cited by 99 · cited 1×
“The C-terminal domain is the minimal lipid-associating domain of ApoA1 and allows binding to lipids with high affinity [206,207].”
BackgroundCurrent and future treatment of amyloid diseases
Ankarcrona, M., Winblad, B. G., Monteiro, C., Fearns, C., Powers, E. T., Johansson, J., Westermark, G. T., Presto, J., Ericzon, B. ‐., & Kelly, J. W. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12506 · Cited by 99 · cited 1×
“All of them are characterized by the aggregation of misfolded proteins which have been found to adopt the same amyloid β-sheet-rich architecture, as part of their nature [1,2].”
BackgroundRobert, J., Stukas, S. K., Button, E. B., Cheng, W. H., Lee, M., Fan, J., Wilkinson, A., Kulić, I., Wright, S. D., & Wellington, C. L. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.10.005 · Cited by 98 · cited 1×
“In treated mice a reduction of soluble Aβ1-42 and Aβ1-40 within 24h has been observed but no effects were observed on Aβ and on inflammation after chronic treatment [246].”
BackgroundMisregulation of Tau Alternative Splicing in Neurodegeneration and Dementia
Andreadis, A. (2006) · Progress in molecular and subcellular biology · doi:10.1007/978-3-540-34449-0_5 · Cited by 97 · cited 2×
“spliced and the transcription leads to the formation of six Tau isoforms [42,43], displaying three or”
BackgroundGregorini, G. A., Izzi, C., Obici, L. P., Tardanico, R., Röcken, C., Viola, B. F., Capistrano, M., Donadei, S., Biasi, L., Scalvini, T., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005040382 · Cited by 97 · cited 1×
“ApoA1-induced amyloidosis often trigger asymptomatic hepatopathy and nephropathy [211].”
BackgroundInactivation of human cystatin C and kininogen by human cathepsin D
Lenarčič, B., Krašovec, M., Ritonja, A., Olafsson, I., & Turk, V. (1991) · FEBS Letters · doi:10.1016/0014-5793(91)80295-e · Cited by 96 · cited 1×
“Furthermore, CysC itself is a target for proteases and its function is inactivated by cathepsin D and elastase [161].”
BackgroundThe Relation between Apolipoprotein A-I and Dementia: The Honolulu-Asia Aging Study
Saczynski, J. S., White, L., Peila, R. L., Rodriguez, B. L., & Launer, L. J. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm027 · Cited by 92 · cited 1×
“ApoA1 levels are also found to be significantly lower in AD patients compared to controls [223] whereas high levels of ApoA1 are associated in lowering risks of dementia [232].”
ResultShin, W. S., Di, J., Cao, Q., Li, B., Seidler, P. M., Murray, K. A., Bitan, G., & Jiang, L. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0541-9 · Cited by 92 · cited 5×
“Aβ-seeds were able to induce Tau aggregation earlier than the usual 24 h of incubation necessary to enhance the Tau-aggregation [84].”
BackgroundInfluentialHuman Serum Transthyretin Levels Correlate Inversely with Alzheimer's Disease
Han, S.-H., Jung, E. S., Sohn, J.-H., Hong, H. J., Hong, H., Kim, J., Na, D. L., Kim, M., Kim, H. Y., Ha, H. J., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-102145 · Cited by 88 · cited 5×
“A direct implication of TTR in AD physiopathology have been confirmed by in vivo studies in AD patients where TTR concentration was observed to decease both in plasma and CSF [117,118].”
BackgroundInfluentialFink, G. R., Driver, J., Rorden, C., Baldeweg, T., & Dolan, R. J. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200004)47:4<440::aid-ana6>3.0.co;2-e · Cited by 82
Ghadami, S. A., Chia, S., Ruggeri, F. S., Meisl, G., Bemporad, F., Habchi, J., Cascella, R., Dobson, C. M., Vendruscolo, M., Knowles, T. P. J., et al. (2020) · Biomacromolecules · doi:10.1021/acs.biomac.9b01475 · Cited by 82 · cited 1×
“Recently, ThT fluorescence spectroscopy analyses showed that both TTR tetramer and monomer bind to Aβ1-40 oligomers and inhibit the primary and secondary nucleation processes, which limits both the toxicity of Aβ1-40 oligomers and the ability of the fibrils to proliferate [126].”
BackgroundGursky, O., Mei, X., & Atkinson, D. (2011) · Biochemistry · doi:10.1021/bi2017014 · Cited by 80 · cited 2×
“Studies with electron paramagnetic resonance spectroscopy [219], X-ray crystallographic studies [220] and hydrogen-deuterium exchange mass spectroscopy [221] showed that the G26R mutation induces helix destabilization of the protein in the N-terminal domain leading to a transition of residues 14-58 to a β-sheet confor…”
BackgroundNakagawa, S. H., Lau, H. S. H., Kezdy, F. J., & Kaiser, E. T. (1985) · Journal of the American Chemical Society · doi:10.1021/ja00310a055 · Cited by 77 · cited 1×
“The C-terminal domain is the minimal lipid-associating domain of ApoA1 and allows binding to lipids with high affinity [206,207].”
BackgroundChang, Y., & Chen, Y. (2014) · FEBS Journal · doi:10.1111/febs.12813 · Cited by 77
APOA1 polymorphism influences risk for early-onset nonfamiliar AD
Vollbach, H., Heun, R., Morris, C. M., Edwardson, J. A., McKeith, I. G., Jessen, F., Schulz, A., Maier, W., & Kölsch, H. (2005) · Annals of Neurology · doi:10.1002/ana.20593 · Cited by 74
The possible place of cathepsins and cystatins in the puzzle of Alzheimer disease: A review
Bernstein, H., Kirschke, H., Wiederanders, B., Kh, P., Zipress, A., & Rinne, A. (1996) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815106 · Cited by 74 · cited 1×
“These cathepsins are studied in AD because it has been observed that cathepsin-immunoreactive material is associated with senile plaques and neurofibrillary tangles [160].”
BackgroundMucchiano, G. I., Jonasson, L., Häggqvist, B., Einarsson, E., & Westermark, P. (2001) · American Journal of Clinical Pathology · doi:10.1309/pje6-x9e5-lx6k-nely · Cited by 74 · cited 2×
“hereditary form, characterized by the wild-type protein deposition [214].”
BackgroundIdentification of beta-amyloid-binding sites on transthyretin
Du, J., Cho, P. Y., Yang, D. T., & Murphy, R. M. (2012) · Protein Engineering Design and Selection · doi:10.1093/protein/gzs026 · Cited by 69 · cited 2×
“The slight discrepancy between the two studies is mainly due to the drawback of the cross-linking that it allows to identify only spatially close domains containing lysine [124].”
BackgroundBeta-Amyloid and Tau-Protein: Structure, Interaction, and Prion-Like Properties
Tatarnikova, O. G., Орлов, М. А., & Bobkova, N. V. (2015) · Biochemistry (Moscow) · doi:10.1134/s000629791513012x · Cited by 69 · cited 1×
“Others, instead, support the idea that it is mainly Tau that plays the major role in the etiopathology, essentially for two reasons: firstly because Tau tangles can be found in patients’ brain even when extracellular Aβ deposits are not present [57], and secondly because evidences proved that intracellular Tau tangles…”
BackgroundMolecules That Mimic Apolipoprotein A-I: Potential Agents for Treating Atherosclerosis
Leman, L. J., Maryanoff, B. E., & Ghadiri, M. R. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4005847 · Cited by 69 · cited 1×
“Lysine and arginine residues in this region are responsible for this strong affinity because they can bury into the membrane the hydrophobic part of their side chains [208,209].”
BackgroundTransthyretin is a metallopeptidase with an inducible active site
Liz, M. A., Leite, S. C., Juliano, L., Saraiva, M. J., Damas, A. M., Bur, D., & Sousa, M. M. (2012) · Biochemical Journal · doi:10.1042/bj20111690 · Cited by 69 · cited 1×
“It has been reported that the same cations interact with TTR [136,137].”
BackgroundKawano, M., Kawakami, M., Otsuka, M., Yashima, H., Yaginuma, T., & Ueki, A. (1995) · Clinica Chimica Acta · doi:10.1016/0009-8981(95)06115-t · Cited by 68 · cited 2×
“Notably, a correlation between the decreased levels of plasmatic ApoA1 and the occurrence and severity of AD has been showed [225].”
BackgroundWallin, C., Hiruma, Y., Wärmländer, S. K. T. S., Huvent, I., Jarvet, J., Abrahams, J. P., Gräslund, A., Lippens, G. M., & Luo, J. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b13623 · Cited by 67 · cited 1×
“Tau-441 does not induce any conformational change in Aβ monomers and, conversely, prevent the formation of β-sheet rich structure [85].”
BackgroundOliveira, S. M., Ribeiro, C. A., Cardoso, I., & Saraiva, M. J. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110488 · Cited by 66
Ribeiro, C. A., Saraiva, M. J., & Cardoso, I. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045368 · Cited by 65 · cited 2×
“In contrast with this data, in vivo experiments reported that the administration of TTR tetrameric stabilizers to AD transgenic mice led to an improvement of pathological conditions, supporting the hypothesis that it is the TTR tetramer that interacts with Aβ peptide [123].”
BackgroundResultAlzheimer’s disease and the cystatin C gene polymorphism: an association study
Beyer, K., Lao, J. I., Gómez, M., Riutort, N., Latorre, P., Mate, J. L., & Ariza, A. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02307-2 · Cited by 64 · cited 1×
“Experimental data suggested a synergistic association among the CST3-A allele, APOE4 and AD in elderly AD patients [179,180].”
BackgroundFichou, Y., Al-Hilaly, Y. K., Devred, F., Smet-Nocca, C., Tsvetkov, P. O., Verelst, J., Winderickx, J., Geukens, N., Vanmechelen, E., Perrotin, A., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0682-x · Cited by 64
Transthyretin as both a Sensor and a Scavenger of β-Amyloid Oligomers
Yang, D. T., Joshi, G., Cho, P. Y., Johnson, J. A., & Murphy, R. M. (2013) · Biochemistry · doi:10.1021/bi4001613 · Cited by 63 · cited 1×
“This second interaction might scavenge the toxic oligomers and prevent them from causing cell death [129].”
Wojtczak, A., Neumann, P., & Cody, V. (2001) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444901006047 · Cited by 63 · cited 1×
“The TTR tetramer assembly is characterized by 222 molecular symmetry which forms, in the middle of the tetramer, two identical funnel-shaped named thyroxine binding sites (T4-BS), located at a dimer–dimer interface [101] (Figure 2A,B).”
BackgroundAlemi, M., Silva, S. C., Santana, I. J., & Cardoso, I. (2017) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12707 · Cited by 63
Mouse and rat cystatin C: Escherichia coli production, characterization and tissue distribution
Håkansson, K., Huh, C.-G., GRUBB, A. O., Karlsson, S., & Abrahamson, M. (1996) · Comparative Biochemistry and Physiology Part B Biochemistry and Molecular Biology · doi:10.1016/0305-0491(96)00025-9 · Cited by 61 · cited 1×
“In healthy people, the CysC concentration in the CSF is six times higher than that of blood plasma [158], as a result of a large expression of this protein by the brain tissue (neurons, astrocytes, endothelial, and microglial cells) [159].”
BackgroundPellegrino, S., Tonali, N., Erba, E., Kaffy, J., Taverna, M., Contini, A., Taylor, M., Allsop, D., Gelmi, M. L., & Ongeri, S. (2017) · Chemical Science · doi:10.1039/c6sc03176e · Cited by 61
Self-citationCellular factors modulating the mechanism of tau protein aggregation
Fontaine, S. N., Sabbagh, J. J., Baker, J., Martinez-Licha, C. R., Darling, A., & Dickey, C. A. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1839-9 · Cited by 60
Orlikowska, M., Jankowska, E., Kolodziejczyk, R., Jaskólski, M., & Szymańska, A. (2010) · Journal of Structural Biology · doi:10.1016/j.jsb.2010.11.009 · Cited by 60 · cited 1×
“Some studies suggested that the swapping dimerization could be the mechanism by which CysC forms oligomers and fibrils [163,171,172], moreover the relationship between the CysC swapping dimerization and its fibrillization has not been clarified yet.”
BackgroundPalaninathan, S. K., Mohamedmohaideen, N. N., Orlandini, E., Ortore, G., Nencetti, S., Lapucci, A., Rossello, A., Freundlich, J. S., & Sacchettini, J. C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006290 · Cited by 58
Human plasma proapoa-I: Isolation and amino-terminal sequence
Brewer, H. B., Fairwell, T., Kay, L. L., Meng, M., Ronan, R., Law, S. W. T., & Light, J. A. (1983) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(83)91772-2 · Cited by 58 · cited 1×
“Human ApoA-1 is synthesized as preproapoA-1, a 267 amino acid precursor ap lipopr tein, which undergoes intracellular co-translational proteolytic cleavage into proapoA-1 and suc essively proapoA-1 is cleaved to mature pla ma ApoA1 in human plasma [195,196].”
BackgroundDal Magro, R., Simonelli, S., Cox, A., Formicola, B., Corti, R., Cassina, V., Nardo, L., Mantegazza, F., Salerno, D., Grasso, G., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00419 · Cited by 58 · cited 1×
“ApoA1 in a discoidal HDL can cross BBB and reduce fibrils amount and extension by remodeling Aβ fibrils [236].”
BackgroundRibeiro, C. A., Oliveira, S. M., Guido, L. F., Magalhães, A., Valencia, G., Arsequell, G., Saraiva, M. J., & Cardoso, I. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-131355 · Cited by 57 · cited 1×
“This was the first in vivo evidence that a TTR-stabilizer might be used as a therapeutic agent for AD [122].”
BackgroundTransthyretin is synthesized in the mammalian eye
Martone, R. L., Herbert, J., Dwork, A., & Schon, E. A. (1988) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(88)80367-x · Cited by 57 · cited 1×
“TTR is mainly synthesized by the liver and the choroid plexus of the brain, in minor amounts in the retina [102] and in human placenta [103].”
BackgroundTransthyretin and the human placenta
Landers, K., Mortimer, R. H., & Richard, K. (2013) · Placenta · doi:10.1016/j.placenta.2013.04.013 · Cited by 57 · cited 1×
“TTR is mainly synthesized by the liver and the choroid plexus of the brain, in minor amounts in the retina [102] and in human placenta [103].”
BackgroundArenas, J. L., Kaffy, J., & Ongeri, S. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.07.008 · Cited by 57 · cited 1×
“Finally, peptidomimetic foldamers give the possibility to mimic the secondary structure of the peptide sequence, generally involved in the interaction [151].”
BackgroundAβ “Stretching-and-Packing” Cross-Seeding Mechanism Can Trigger Tau Protein Aggregation
Qi, R., Luo, Y., Wei, G., Nussinov, R., & Ma, B. (2015) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.5b01447 · Cited by 56
Tau pathogenesis is promoted by Aβ1-42 but not Aβ1-40
Hu, X., Li, X., Zhao, M., Gottesdiener, A., Luo, W., & Paul, S. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-52 · Cited by 55 · cited 1×
“Aβ1-40 does not seem to promote Tau phosphorylation but conversely decreases the phosphorylation at Ser262, thus maintaining the binding of Tau to microtubules [94].”
BackgroundKaffy, J., Brinet, D., Soulier, J. L., Correia, I., Tonali, N., Fabiana, F. K., Iacone, Y., Hoffmann, A. R. F., Khemtémourian, L., Crousse, B., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01629 · Cited by 54
Self-citationSantos, L. M., Rodrigues, D. F., Alemi, M., Silva, S. C., Ribeiro, C. A., & Cardoso, I. (2016) · Molecular Medicine · doi:10.2119/molmed.2016.00124 · Cited by 54 · cited 1×
“They hypothesized that the instability of TTR tetramer in AD leads to accelerated clearance and lower level [146].”
BackgroundSmall molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation
Xi, M., Chen, Y., Yang, H., Xu, H., Du, K., Wu, C., Xu, Y., Deng, L., Luo, X., Yu, L., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.04.036 · Cited by 54
McAllister, B. B., Lacoursiere, S. G., Sutherland, R. J., & Mohajerani, M. H. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.01.026 · Cited by 54 · cited 1×
“Since a very recent and detailed review about the in vivo intracerebral seeding of Aβ and Tau in mice [72], has just been released, we will mainly focus on the in vitro studies aiming to deepen the knowledge about the physicochemical aspects of this interaction.”
BackgroundImamura, T., Yanagihara, Y. T., Ohyagi, Y., Nakamura, N., Iinuma, K. M., Yamasaki, R., Asai, H., Maeda, M., Murakami, K., Irie, K., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104739 · Cited by 53 · cited 1×
“This in vivo study conducted on AD mouse model proved that the attenuation of insulin signaling is involved in an increase of toxic Aβ1-42 conformer levels which promotes not only an increase in p-Tau but also a direct interaction between the two misfolded proteins with the formation of their co-aggregates [67].”
BackgroundQuintela, T., Gonçalves, I., Baltazar, G., Alves, C. H., Saraiva, M. J., & Santos, C. R. A. (2009) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-008-9339-1 · Cited by 52
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Jiménez-Balado, J., & Eich, T. S. (2021) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2021.01.005 · Cited by 183
“Recent work suggests that tau and Aβ are interconnected, and together trigger the neurodegeneration in the brain that ultimately results in AD [18-20].”
BackgroundLimorenko, G., & Lashuel, H. A. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00127b · Cited by 162
Proteostasis and neurodegeneration: a closer look at autophagy in Alzheimer's disease
Barmaki, H., Nourazarian, A., & Khaki-Khatibi, F. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1281338 · Cited by 87
Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy
Fang, Y., Wang, J., Zhao, M., Zheng, Q., Ren, C., Wang, Y., & Zhang, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00844 · Cited by 100
Metadata
- Authors
- Ciccone, L., Shi, C., di Lorenzo, D., Van Baelen, A.-C., & Tonali, N.
- Affiliations
- University of Pisa (IT)
- Centre National de la Recherche Scientifique (FR)
- CNRS, BioCIS, Université Paris-Saclay, rue Jean-Baptiste Clément 5, 92290 Châtenay-Malabry, France
- Département Médicaments et Technologies pour la Santé (DMTS), CEA, INRAE, Université Paris Saclay, SIMoS, 91191 Gif-sur-Yvette, France
- Corresponding author
- Ciccone, Lidia
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-05-23
- Volume
- 25
- Issue
- 10
- Pages
- 2439
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC7288020
- OpenAlex
- W3027358274
- Cited by
- 69
- References
- 256
- Citations by year
- 2026: 5 · 2025: 16 · 2024: 6 · 2023: 11 · 2022: 11 · 2021: 15 · 2020: 5
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion, cc-by)
- HAL (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Horizon 2020 (860070)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta 42, co-assembly, protein-protein interaction, tau aggregation, prealbumin, cystatin C, apolipoprotein A-I, treatment options
- MeSH terms
- Alzheimer Disease, Amyloid, Humans, Peptide Fragments, Prealbumin, Amyloid beta-Peptides, Apolipoprotein A-I, tau Proteins, Cystatin C, Protein Interaction Maps, Protein Aggregation, Pathological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.